Cytisinicline well tolerated with only 2.9 percent of participants discontinuing due to an adverse event

Reduced risk seen for all CVD events, respiratory system disease events, hospitalization due to CVD or RSD, adverse birth outcomes

Adjusted prevalence of nicotine dependence was lower for those aged 18 to 25, 26 to 34, 35 to 49 versus those aged 50 and older

No significant difference in verified seven-day abstinence seen by treatment group among Black adults who smoke daily

Decreases in depression, anxiety seen, particularly in people with history of mental illness

App use tied to higher six-month biochemically verified sustained abstinence rate

However, early electronic cigarette quitters plus stable cigarette use was the most common trajectory in 41.6 percent of participants

Health system-based care produced better treatment use and more tobacco abstinence than community-based quitlines

Safety of e-cigarettes in pregnancy is similar to that of nicotine patches while possibly more effective

Low-burden, point-of-care program may increase access to and impact of treatment to assist tobacco cessation